EMEA-000380-PIP06-19

Key facts

Invented name
Cosentyx
Active substance
Secukinumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0112/2021
PIP number
EMEA-000380-PIP06-19
Pharmaceutical form(s)
  • Solution for injection
  • Powder for solution for injection
Condition(s) / indication(s)
Treatment of Systemic Lupus Erythematosus (SLE)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613246715

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating